Figure 1From: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled studyEffect of six month therapy with trimetazidine or placebo on top of usual medical care in patients with type 2 diabetes. Trimetazidine significantly reduced left ventricular end diastolic (LVEDD) and end systolic (LVESD) diameters compared to both baseline examination and placebo. TMZ = Trimetazidine, PBO = PlaceboBack to article page